

## Bevasiranib sodium

Cat. No.:	HY-153484A
CAS No.:	849758-52-7
Molecular Weight:	14224
Target:	VEGFR; Small Interfering RNA (siRNA)
Pathway:	Protein Tyrosine Kinase/RTK; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

## Bevasiranib (sodium)

### BIOLOGICAL ACTIVITY

#### Description

Bevasiranib sodium is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neovascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).

### REFERENCES

- [1]. Garba AO, Mousa SA. Bevasiranib for the treatment of wet, age-related macular degeneration. *Ophthalmol Eye Dis.* 2010;2:75-83.
- [2]. Dejneka NS, Wan S, Bond OS, Kornbrust DJ, Reich SJ. Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. *Mol Vis.* 2008;14:997-1005.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA